Arix Bioscience's portfolio company, Sorriso Pharmaceuticals, has announced that the first subject has been dosed in the Phase 1/1b clinical trial of SOR102. SOR102 is an oral biologic treatment being developed for the treatment of inflammatory bowel disease (IBD). The trial will evaluate the safety, tolerability, pharmacokinetics, and clinical and biological activity of SOR102 in healthy participants and patients with mild to severe ulcerative colitis. The trial is expected to enroll up to 60 adult participants at sites in the UK and Europe. Sorriso CEO Ciara Kennedy believes that SOR102 has the potential to be an oral first-line advanced therapy with a superior efficacy and safety profile compared to existing treatments. Arix CEO Robert Lyne sees this milestone as an exciting next step for Sorriso and looks forward to seeing SOR102 develop through the Phase 1 trial.